Buprenorphine and buprenorphine/naloxone diversion, misuse, and Illicit use: An international review

Current Drug Abuse Reviews

Volumn 4, Issue 1, 2011, Pages 28-41

  Yokell, Michael A ^a   Zaller, Nickolas D ^a,b   Green, Traci C ^a,b,c   Rich, Josiah D ^a,b  

^a MIRIAM HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone; Diversion; Injection drug use; Opiate abuse; Opiate dependence; Opioid abuse; Opioid dependence; Self treatment; Suboxone; Subutex

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; PLACEBO; PROBUPHINE; TAMGESIC; TIDIGESIC; UNCLASSIFIED DRUG;

CHRONIC PAIN; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG CONTROL; DRUG DIVERSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MISUSE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EUPHORIA; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LOW BACK PAIN; LOW DRUG DOSE; MEDICAL PARAMETERS; MOTIVATION; OPIATE ADDICTION; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SELF MEDICATION; SUBSTANCE ABUSE; SUBSTITUTION THERAPY;

EID: 79954558512     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473711104010028     Document Type: Review

References (141)

1. [Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006; 82 (Suppl 3): iii56-63.
2. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Managed Care Pharm 2009; 15(7): 1-7.
3. [United Nations Office on Drugs and Crime. World Drug Report 2007.
4. World Health Organization, WHO Drug Information 2005; 19(3): 72.
5. [World Health Organization; Office on Drugs and Crime. Drug Report 2007.
6. World Health Organization; UNAIDS Joint Program on HIV/AIDS. Consensus Statement of the Reference Group to the United Nations on HIV and Injecting Drug Use WHO 2010; 2010; 1-152.
7. [World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO 2009; 1-134.
8. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34(2): 165-73.
9. Ho R, Ho E, Mak A. Cutaneous complications among i.v. buprenorphine users. J Dermatol 2009; 36(1): 22-9.
10. Sande M, Volberding P. The Medical Management of AIDS. 1999, Philadelphia: WB Saunders.
11. Volkow ND, Li TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 2004; 5(12): 963-70.
12. Dole V, Nyswander M. A Medical Treatment for Diacetlymorphine (Heroin) Addiction. JAMA 1965; 193(8): 80-4.
13. Physicians' Desk Reference 2009. 63rd ed. Montvale, NJ: Physicians' Desk Reference: 2009
14. Mattick RP, Breen C, Kimber J, Davoli J. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: 1-17.
15. Mattick RP, Ali R, White J, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4): 441-52.
16. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 2: 1-51.
17. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93(4): 515-32.
18. National Institutes of Health. Interventions to Prevent HIV Risk Behaviors. Consensus Development Conference Statement 1997; 15(2): 1-41.
19. Gowing LR, Farrell M, Bornemann R, Sullivan L, Ali R. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21(2): 193-5.
20. Walsh SL, Preston K, Stitzer M, Cone E, Bigelow G. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55(5): 569-80.
21. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry 2001; 158(8): 1200-4.
22. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44(7): 661-80.
23. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006; 43 (Suppl 4): S173-7.
24. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61(1): 85-94.
25. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 2003; 70 (2 Suppl): S29-37.
26. Rolly G, Versichelen L. Buprenorphine as postoperative analgesic. Acta Anaesthesiologica Belgica 1976; 3: 183-6.
27. Adriaensen H, Van De Walle J. Clinical use of buprenorphine in chronic administration Acta Anaesthesiologica Belgica 1976; 3: 1-5.
28. Harper I. Tamgesic Abuse. New Zealand Med J 1983; 96(741): 777.
29. Strang J. Abuse of buprenorphine. Lancet 1985; 2(8457): 725.
30. Bourin M, Zhiji C, DeLima L, WHO Expert Committee on Drug Dependence: Thirty-third Report. WHO 2003; 1-31.
31. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13 (Suppl 1): S17-28.
32. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207 (4431): 657-9.
33. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat 2010; 39(1): 41-50.
34. Blaine J, Ed. United States National Institutes of Health; National Institute on Drug Abuse (NIH/NIDA). Buprenorphine: an alternative treatment for opioid dependence, in NIDA Research Monograph Series. 1992.
35. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267(20): 2750-5.
36. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003; 179(1): 38-42.
37. Amass L, Ling W, Freese TE, et al. Bringing buprenorphinenaloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13 (Suppl 1): S42-66.
38. Fiellin DA, O'Connor PG. Clinical practice: Office-based treatment of opioid-dependent patients. N Engl J Med 2002; 347(11): 817-23.
39. Bridge TP, Fudala PJ, Hebert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003; 70 (2 Suppl): S79-85.
40. Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 1996; 60(1): 105-14.
41. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70 (2 Suppl): S13-27.
42. Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology (Berl) 2010; 211(3): 303-12.
43. Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 2009; 31(3): 503-13.
44. Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, doubleblind, placebo-controlled crossover study, followed by an openlabel extension phase. Clin Ther 2010; 32(5): 844-60.
45. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005; 12(5): 379-84.
46. James IGV, O'Brien CM, McDonald CJ. A randomized, doubleblind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage 2010; 40(2): 266-78.
47. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13(3): 219-30.
48. [Buprenorphine [webpage on the Internet]. United States Substance Abuse and Mental Health Services Administration (SAMHSA): Center for Substance Abuse Treatment (CSAT). [update 2010; cited 2010 October]; Available from: http://buprenorphine.samsha.gov.
49. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43 (Suppl 4): S197-215.
50. Winstock AR, Lea T. Diversion and Injection of Methadone and Buprenorphine Among Clients in Public Opioid Treatment Clinics in New South Wales, Australia. Subst Use Misuse 2010; 45(1-2): 240-52.
51. [New South Wales Department of Health. Opioid Treatment Program: Clinical Guidelines for methadone and buprenorphine treatment. 2006: Sydney, Australia. 183.
52. Lintzeris N. Australian National Clinical Guidelines and Procedures for the use of buprenorphine in the maintenance treatment of opioid dependence. Australian Government: National Drug Strategy 2006: 1-82.
53. Basu D, Mattoo SK, Malhorta A, Gupta N, Malhorta R. A longitudinal study of male buprenorphine addicts attending an addiction clinic in India. Addiction 2000; 95(9): 1363-72.
54. [Kumar MS, Natale R, Langkham B, Sharma C, Kabi R, Mortimore G. Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded. Harm Reduct J 2009; 6: 4.
55. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 35(2): 68-72.
56. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35(4): 501-16.
57. Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 1993; 53(5): 570-6.
58. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002; 303(2): 695-703.
59. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 2002; 301(1): 266-76.
60. Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005; 315(3): 1320-30.
61. Bedi N, Ray R, Jain R, Dhar N. Abuse Liability of buprenorphine-- a study among experienced drug users. Indian J Physiol Pharmacol 1998; 42(1): 95-100.
62. Sigmon SC, Moody DE, Nuwsayer ES, Bigelow GE. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 2006; 101(3): 420-32.
63. Baumevieille M, Haramburu F, Bégaud B. Abuse of prescription medicines in southwestern France. Ann Pharmacother 1997; 31(7-8): 847-50.
64. [Vicknasingam B, Mazlan M, Schottenfeld R, Chawarski M. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010: 6 [In Press]
65. Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berl) 1997; 129(4): 329-38.
66. Wesson DR, Smith DE. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs 2010; 42(2): 161-75.
67. Collins GB, MS McAllister. Buprenorphine maintenance: a new treatment for opioid dependence. Cleve Clin J Med 2007; 74(7): 514-20.
68. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988; 247(1): 47-53.
69. Comer SD, Sullivan M, Whittington RA, Vosberg S, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 2008; 33(5): 1179-91.
70. Moatti JP, Vlahov D, Feroni I, Perrin V, Odabia Y. Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. Eur Addict Res 2001; 7(1): 40-5.
71. Bouchez J, Vignau J. The French experience--the pharmacist, general practitioner and patient perspective. Eur Addict Res 1998; 4 (Suppl 1): 19-23.
72. Boeuf O, Lapeyre-Mestre M, French Network of Centers for Evaluation and Information Pharmacodependence (CEIP), Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf 2007; 30(3): 265-76.
73. Lapeyre-Mestre M, Damase-Michel C, Adams P, Michaud P, Montastruc JL. Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrénées. Eur J Clin Pharmacol 1997; 52(1): 37-9.
74. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96(2): 267-72.
75. Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addictive Behaviors 2008; 33(12): 1625-9.
76. [Strang J. Abuse of buprenorphine (Temgesic) by snorting. BMJ 1991; 302(6782): 969
77. Aalto M, Halme J, Visapaa J, Salaspuro M. Buprenorphine Misuse in Finland. Subst Use Misuse 2007; 42(6): 1027-8.
78. [Finland (Overview) [webpage on the Internet]. European Monitoring Centre for Drugs and Drug Addiction [updated 2010; cited 2010 October]; Available from: http://www.emcdda.europa.eu.
79. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88(1): 75-8.
80. Hakansson A, Medvedeo A, Andersson M, Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur Addict Res 2007; 13(4): 207-15.
81. Lavelle TL, Hammersley R, Forsyth A. The use of buprenorphine and temazepam by drug injectors. J Addict Dis 1991; 10(3): 5-14.
82. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow--an increase. Br J Addict 1989; 84(4): 439-41.
83. Mounteney J, Haugland S. Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Int J Drug Policy 2009; 20(2): 161-9.
84. O'Connor JJ, Moloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988; 83(9): 1085-7.
85. San L, Torrens M, Castillo C, Porta M, de la Torre R. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. Addiction 1993; 88(10): 1341-9.
86. [Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. Int J Drug Policy 2010: 5 [Article in Press].
87. Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia--an update. Drug Alcohol Rev 2008; 27(2): 197-9.
88. Jenkinson R, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100(2): 197-205.
89. Winstock AR, Lea T, Jackson AP. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. J Addict Dis 2009; 28(1): 57-63.
90. Winstock, AR, Lea T, Sheridan J. What Is Diversion of Supervised Buprenorphine and How Common Is It? J Addict Dis 2009; 28(3): 1-11.
91. [DEA: Drugs of concern: Buprenorphine [homepage on the Internet]. United States Department of Justice, Drug Enforcement Agency (DEA) [cited 2011 January]. Available from: http://www.deadiversion.usdoj.gov/drugs_concern/buprenorphine.htm
92. Fudala PJ, Bridge TP, Hebert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349(10): 949-58.
93. [Reckitt Benckiser Pharmaceuticals Inc. Suboxone and Subutex: US Prescribing Information. 2006.
94. [United States Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol 40 (TIP 40): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction 2004: 169.
95. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6(10): 662-72.
96. Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: A pilot study and descriptive comparison. Clin Toxicol 2007; 45(2): 144-51.
97. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90(1): 64-71.
98. Schneider MF, Bailey JE, Cicero TJ, et al. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol Drug Saf 2009; 18(9): 778-90.
99. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis 2007; 26(3): 107-11.
100. Monte A, Mandell T, Wilford B, Tennyson J, Boyer E. Diversion of Buprenorphine/Naloxone Coformulated Tablets in a Region with High Prescribing Prevalence. J Addict Dis 2009; 28(3): 226-31
101. [Bazazi AR, Yokell M, Fu J, Zaller ND, Rich JD. Illicit use of buprenorphine/naloxone among injecting and non-injecting opioid users. J Add Med 2011. [In Press]
102. Mazlan M, Schottenfeld RS, Chawarski MC. New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Rev 2006; 25(5): 473-8.
103. Panda S, Kumar MS, Lokabiraman S, et al. Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr 2005; 39(1): 9-15.
104. Solomon SS, Desai M, Srikrishnan A, et al. The Profile of Injection Drug Users in Chennai, India: Identification of Risk Behaviours and Implications for Interventions. Subst Use Misuse 2010; 45(3): 354-67.
105. Chatterjee A, Uprety L, Chapagain M, Kafle K. Drug abuse in Nepal: a rapid assessment study. Bull Narc 1996; 48(1-2): 11-33.
106. Panda S, Chatterjee A, Sarkar S, et al. Injection drug use in Calcutta: a potential focus for an explosive HIV epidemic. Drug Alcohol Rev 1997; 16(1): 17-23.
107. Chong E, Poh KK, Shen L, Yeh IB, Chai P. Infective endocarditis secondary to intravenous Subutex abuse. Singapore Med J 2009; 50(1): 34-42.
108. Bruce RD, Govidasamy S, Sylla L, Haddad M, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse 2008; 34(4): 511-7.
109. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12(5): 577-81.
110. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997; 37(1): 31-7.
111. JBS International, Maxwell JC. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators. Report Submitted to SAMHSA 2006: 70.
112. Chowdhury AN, Chowdhury S. Buprenorphine abuse: report from India. Br J Addict 1990; 85(10): 1349-50.
113. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69(2): 175-81.
114. Kumar M, Mudaliar S, Thyagarajan S, Kumar S, Selvanayagam A, Daniels D. Rapid assessment and response to injecting drug use in Madras, south India. Int J Drug Policy 2000; 11(1-2): 83-98.
115. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008; 35(1): 87-92.
116. Otiashvili D, Zabransky T, Kirtadze I, Piralishvili G, Chavchanidze M, Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine? Eur Addict Res 2010; 16(1): 1-8.
117. Ho R, Ho E, Tan C, Mak A. Pulmonary Hypertension in First Episode Infective Endocarditis among Intravenous Buprenorphine Users: Case Report. Am J Drug Alcohol Abuse 2009; 35(3): 199-202.
118. Partanen TA, Vikatmaa P, Tukiainen E, Lepantelo M, Vuola J. Outcome after Injections of Crushed Tablets in Intravenous Drug Abusers in the Helsinki University Central Hospital. Eur J Vascular Endovasc Surg 2010; 37(6): 704-11.
119. Green TC, Bowman S. Association between initiation of nonmedical use of prescription opioids and initiation of injection and heroin use in a national sample of drug users. Proceedings of the Harm Reduction Coalition Conference. 2010 Austin, TX, USA.
120. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003; 70(2 Suppl): S59-77.
121. Orman JS, Keating GM. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs 2009; 23(10): 899-902.
122. Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002; 8(4): 377-90.
123. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121(1-2): 65-9.
124. Bell JR, Butler B, Lawrence A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104(1-2): 73-7.
125. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285(1): 45.
126. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend 2009; 99(1-3): 222-30.
127. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010; 39(4): 340-52.
128. Pradel V, Frauger E, Thirion X, et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18(1): 36-43.
129. Spiller H, Lorenz DJ, Bailey EJ, Dart R. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 2009; 28(2): 130-6.
130. Tacke U, Uosukainen H, Kananen M, Kontra K, Pentikänen H. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination. J Opioid Manag 2009; 5(6): 321-9.
131. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40(1): 27-35.
132. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternateday buprenorphine dosing is preferred to daily dosing by opioiddependent humans. Psychopharmacology 1998; 136(3): 217-25.
133. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58(1-2): 143-52.
134. White J, Bell J, Saunders J, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103(1-2): 37-43.
135. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction 2007; 102(10): 1648-56.
136. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology 2008; 198(2): 149-158.
137. Reckitt Benckiser Pharmaceuticals Inc. SUBOXONE Sublingual Film [package insert]. Richmond, VA, USA. 2010.
138. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008: 51.
139. Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend 1997; 47(3): 227-35.
140. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health 2010; 87(4): 592-602.
141. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9(5): 358-64.